SUNRISE, Fla., Dec. 3, 2010 (GLOBE NEWSWIRE) -- Bioheart Inc. (OTCBB:BHRT) -- Bioheart, Inc. is one of the presenters at the upcoming 3rd Annual LD MICRO conference on Thursday, December 9, 2010, at 4:00 p.m. (PST) at the Luxe Sunset Bel Air, Los Angeles, California.
The LD MICRO Conference presents eighty corporations to institutional investors focused on small and micro-cap companies. Last year's conference attracted over 450 investment professionals.
Howard J. Leonhardt, Bioheart's founder and Chief Technology Officer, will be presenting the company's products for treating heart failure including the flagship product MyoCell, muscle derived stem cells for treating patients in advanced heart failure. Bioheart is focused on securing funding to continue part 2 of the MARVEL phase II/III trial. In the first part of this trial, the treated patients, on average, had a 91 meter improvement in their six minute walk distance while placebo patients declined 4 meters.
About Bioheart, Inc.
Bioheart is committed to maintaining a leading position within the cardiovascular sector of the cell technology industry, delivering cell therapies, intelligent devices and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The company's goals are to enable damaged tissue to be regenerated, if possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. MyoCell is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
For more information on Bioheart, visit .
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2009, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010.
CONTACT: Bioheart Inc. Catherine Sulawske Guck, Chief Operating Officer 954 835 1500